Novartis files for approval of RAD001 for kidney cancer
This article was originally published in Scrip
Executive Summary
Novartishas filed its first approval applications for its targeted anticancer RAD001 (everolimus), proposed brand name Afinitor, in the US, the EU and Switzerland for the treatment of patients with advanced kidney cancer who have failed on standard treatment.